NEW YORK (GenomeWeb News) – BioFire Diagnostics has appointed Robert Lollini as CFO.

Lollini most recently served as CEO, and formerly as CFO of Myrexis, a Utah-based biotechnology company. He remains a member of its board of directors. From 1993 to 2007, Lollini held multiple executive positions at drug-delivery company Iomed, which was acquired in May 2007. Earlier in his career, he held various executive management positions at RP Scherer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.